VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

EAU 2022 | The case against including genomics in defining high-risk prostate cancer

Steven Joniau, MD, PhD, University Hospitals Leuven, Leuven, The Netherlands, gives an overview of why genomic testing should not be incorporated in staging prostate cancer. Access to genetic testing is scant, with only BRCA gene testing available. Current staging of prostate cancer is typically carried out with clinical parameters such as PET CT scans and incorporating genomic markers may result in redefining treatment regimens and clinical practice. This interview took place at the European Association of Urology (EAU) Meeting 2022.


Prof. Joniau reports the following conflicts of interest:
Research funding:  Astrellas, Bayer, Ferring, Janssen, MDX Health, Roche
Speakers fee: Astrellas, AstraZeneca, Bayer, Ferring, GSK, Ipsen, Janssen, Pfizer, Sanofi
Consultation fee: Astrellas, Bayer, Ipsen, Janssen, Roche

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter